Werewolf Therapeutics (HOWL) Projected to Post Earnings on Tuesday

Werewolf Therapeutics (NASDAQ:HOWL) will likely be posting its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Werewolf Therapeutics to post earnings of ($0.35) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 9:30 AM ET.

Werewolf Therapeutics Stock Up 1.7%

Shares of HOWL stock opened at $0.63 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics has a one year low of $0.53 and a one year high of $2.38. The company’s fifty day moving average price is $0.64 and its 200-day moving average price is $1.08. The company has a market capitalization of $30.67 million, a price-to-earnings ratio of -0.39 and a beta of 0.78.

Insider Activity at Werewolf Therapeutics

In other news, Director Luke Evnin sold 108,606 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66. Following the completion of the transaction, the director owned 2,550,674 shares in the company, valued at $1,555,911.14. This trade represents a 4.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 891,850 shares of company stock worth $635,050. 23.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Regal Investment Advisors LLC increased its stake in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics during the second quarter valued at $48,000. AQR Capital Management LLC bought a new position in Werewolf Therapeutics during the first quarter valued at $79,000. Finally, Bridgeway Capital Management LLC grew its stake in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after buying an additional 62,414 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. HC Wainwright cut their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research note on Friday, December 19th. Citigroup cut Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, January 21st. Finally, Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.